Sorafenib Resistance in Hepatocellular Carcinoma: The Relevance of Genetic Heterogeneity

Despite advances in biomedicine, the incidence and the mortality of hepatocellular carcinoma (HCC) remain high. The majority of HCC cases are diagnosed in later stages leading to the less than optimal outcome of the treatments. Molecular targeted therapy with sorafenib, a dual-target inhibitor targe...

Descripción completa

Detalles Bibliográficos
Autores principales: Cabral, Loraine Kay D., Tiribelli, Claudio, Sukowati, Caecilia H. C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352671/
https://www.ncbi.nlm.nih.gov/pubmed/32549224
http://dx.doi.org/10.3390/cancers12061576

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352671/
https://www.ncbi.nlm.nih.gov/pubmed/32549224
http://dx.doi.org/10.3390/cancers12061576

Ejemplares similares